What ServiceNow (NOW)'s New AI-Focused Legal Chief Means For Shareholders
ServiceNow, Inc. NOW | 102.00 | -1.96% |
- In early January 2026, ServiceNow announced that former Microsoft Chief Legal Officer Hossein Nowbar has joined as President and Chief Legal Officer, while long-time CLO Russ Elmer moved into a Special Counsel role to support continuity across global legal, compliance, governance, and risk functions.
- This leadership shift brings deep experience in AI regulation, data privacy, intellectual property, and geopolitical issues into ServiceNow just as it pushes further into AI-native workflows and large-scale cybersecurity through recent acquisitions like Armis and Moveworks.
- Next, we’ll examine how Nowbar’s AI and regulatory expertise could influence ServiceNow’s AI-centric investment narrative and long-term growth ambitions.
This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
ServiceNow Investment Narrative Recap
To own ServiceNow, you need to believe in its role as a core AI workflow and cybersecurity platform, supported by consistent revenue and earnings growth. Near term, the biggest catalyst is how the market reacts to upcoming Q4 2025 results and AI adoption trends, while integration and execution around recent acquisitions remain a key risk. The Hossein Nowbar appointment does not materially change those near term drivers, but it does speak to how ServiceNow is preparing for tighter AI and data regulation.
Among recent announcements, the planned US$7.75 billion Armis acquisition is most relevant here. It pushes ServiceNow deeper into cyber exposure management just as regulators, customers, and partners focus more on AI, security, and data governance. Combined with Moveworks and the broader AI platform push, this deal sits at the heart of the current catalyst: proving that AI native workflows can support durable growth while managing the complexity and risk of larger, security heavy acquisitions.
Yet beneath the AI opportunity, investors should also be aware of the less visible risk that integration missteps across Armis, Moveworks, and new AI offerings could...
ServiceNow's narrative projects $20.3 billion revenue and $3.3 billion earnings by 2028. This requires 18.9% yearly revenue growth and roughly a $1.6 billion earnings increase from $1.7 billion today.
Uncover how ServiceNow's forecasts yield a $225.84 fair value, a 59% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming revenues could reach about US$20.3 billion and earnings US$4.2 billion by 2028, which is far more bullish than the baseline view and could be challenged or reinforced as leadership changes and AI regulations evolve, so it is worth weighing how differently you might see those risks and rewards.
Explore 23 other fair value estimates on ServiceNow - why the stock might be worth just $198.97!
Build Your Own ServiceNow Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your ServiceNow research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free ServiceNow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ServiceNow's overall financial health at a glance.
No Opportunity In ServiceNow?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
